Grown Rogue International (GRUSF) EBITDA (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly EBITDA came in at $99655.0 in Q1 2026, up 114.05% year-on-year from $46557.4 in Q1 2025, and down 100.0% quarter-over-quarter from $1434.9 billion in Q4 2025.
Grown Rogue International (GRUSF) EBITDA (2009 - 2026) Analysis & Trends
Grown Rogue International's EBITDA history runs 17 years deep, the most recent figure standing at $99655.0 for Q1 2026.
- On a quarterly basis, EBITDA rose 114.05% year-over-year to $99655.0 in Q1 2026; TTM through Mar 2026 was -$872890198.8 billion, a 546137675034861.25% decrease from a year earlier, with the FY2025 full-year figure at -$593487.0, down 1089.44% from the prior year.
- EBITDA eased to $99655.0 in Q1 2026 per GRUSF's latest filing, from $1434.9 billion in the prior quarter.
- Across five years, EBITDA topped out at $1434.9 billion in Q4 2025 and bottomed at -$872892000.0 billion in Q2 2025.
- The 5-year median for EBITDA is $646805.0 (2023), against an average of -$58192679.9 billion.
- Biggest YoY gain for EBITDA was 2392297594.27% in 2025; the steepest drop was 935860437431563.9% in 2025.
- Year by year, EBITDA stood at $486613.0 in 2022, then fell by 12.42% to $426154.0 in 2023, then slumped by 85.93% to $59980.0 in 2024, then surged by 2392297594.27% to $1434.9 billion in 2025, then tumbled by 100.0% to $99655.0 in 2026.
- Per Business Quant, the three latest GRUSF EBITDA figures stand at $99655.0 (Q1 2026), $1434.9 billion (Q4 2025), and $366.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 99,655.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99,655.00 |
| Dec 31, 2025 | 1,434.90 Bn |
| Sep 30, 2025 | 366.34 Bn |
| Jun 30, 2025 | -872,892,000.00 Bn |
| Mar 31, 2025 | -709,401.00 |
| Dec 31, 2024 | 59,979.97 |
| Sep 30, 2024 | 715,979.13 |
| Jun 30, 2024 | 93,271.60 |
| Mar 31, 2024 | 927,094.00 |
| Dec 31, 2023 | 426,154.00 |
| Oct 31, 2023 | 1.65 Mn |
| Jul 31, 2023 | 907,481.35 |
| Apr 30, 2023 | 826,790.00 |
| Jan 31, 2023 | 646,805.00 |
| Jan 31, 2022 | 486,613.00 |
| Oct 31, 2021 | 1.66 Mn |
| Jul 31, 2021 | 715,532.00 |
| Apr 30, 2021 | 142,622.48 |
| Jan 31, 2021 | -987,066.00 |
| Oct 31, 2020 | -3.05 Mn |